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ABSTRACT
Introduction: Severe hypoglycemia is a burden
for both patients and the healthcare system
payer alike. This study aimed to quantify the
resource use associated with a severe
hypoglycemic event (SHE) in patients with
diabetes.
Methods: This retrospective cohort study
compared resource use (e.g., physician visits,
hospitalizations, and medications) 1 month
pre- and post-SHE among patients with type 1
(T1D) or type 2 diabetes (T2D) from a large
not-for-profit healthcare provider.
Results: From 2005 to 2014, 284 patients with
T1D (52.5% male, mean age 29.8 years, mean
HbA1c 7.9%) and 3691 patients with T2D
(47.6% male, mean age 67.1 years, mean
HbA1c 7.3%) were eligible for inclusion in the
study. In total, 95.4% of patients with T1D and
32.8% of patients with T2D were insulin
treated, while 3.5% of patients with T1D and
70.4% of patients with T2D were treated with
oral drugs that could cause hypoglycemia
(sulfonylureas or meglitinides). Hospital
admissions increased by 95% in T1D and
127% in T2D (P\0.001) 1 month post-SHE
versus 1 month pre-SHE. Of those admitted to
hospital (T1D n = 59; T2D n = 1214), the mean
length of stay was significantly longer during
the month post- versus pre-SHE [2.08 vs.
0.88 days, P = 0.036 (T1D) and 4.17 vs.
1.45 days, P\0.001 (T2D)]. Outpatient visits
also increased by 37% for T1D and 47% for T2D
between these two time periods (P\0.001). The
total monthly expense per patient increased by
46% and 87% for T1D and T2D, respectively,
from $485 pre-SHE to $708 post-SHE for T1D,
and from $601 pre-SHE to $1121 post-SHE for
T2D (P\0.001). The greatest expense was
hospital care, with increases of 179% and
166% for T1D and T2D, respectively, to $312
and $706 per patient/month.
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Conclusion: This real-world analysis from a
large diabetes registry indicates an increased
use of healthcare services, including more
frequent and prolonged hospital admissions
and outpatient visits after an SHE, which





Hypoglycemia is a common and serious side
effect associated with glucose-lowering
therapies. Hypoglycemia occurs frequently in
insulin-treated patients, and prevalence is
higher in patients with type 1 diabetes (T1D)
than type 2 diabetes (T2D), but increases in
frequency in T2D with disease duration as
treatment intensifies [1–3]. Hypoglycemia is a
major burden for the healthcare sector and
society, due to the treatment cost and the
associated lost productivity [4–6]; it is also a
burden for patients, resulting in fear and
anxiety, and disruption to their sleep, and
their domestic and social life [4, 7, 8].
Moreover, hypoglycemia is associated with
death, adverse cardiovascular outcomes,
dementia, falls, and fractures [9]. Furthermore,
hypoglycemia can occur suddenly and with
varying severity [4, 9]. Severe hypoglycemic
events (SHEs, requiring third-party assistance)
may require hospitalization and inpatient care,
leading to significant resource use and costs
[10–12].
The aim of this study was to quantify the
resource use and expense associated with an
SHE in adult patients with diabetes, using the
Maccabi Healthcare Services (MHS) database
registry. The majority of studies investigating
resource use following hypoglycemia provide
retrospective data on resource use after an
event, with many only including patients who
report resource use. This study is unique in that
data were collected before and after an SHE for a
designated time period, enabling assessment of
the change in resource use after an SHE. The
time period under consideration for this
analysis was 1 month pre-SHE and 1 month
post-SHE.
METHODS
MHS is the second-largest Health Management
Organization (HMO) in Israel, serving 25% of
the country’s total population with
approximately two million members. Since
1997, information on all members’
interactions with MHS has been collected,
including diagnoses, visits to primary and
secondary care physicians, visits to outpatient
clinics, hospitalizations, laboratory tests, and
purchased and dispensed medications.
This observational, retrospective,
non-interventional, cohort study analyzed
de-identified patients’ electronic medical
record (EMR) data to compare resource use
1 month before and after the date that the
index SHE was reported. The inclusion criteria
for the MHS diabetes registry have been
described previously [13, 14]. Briefly, the
registry used criteria defined by the American
Diabetes Association and included any patient
with one or more of the following: HbA1c
C7.25%, blood glucose (BG) C11.1 mmol/L, a
preceding diagnosis of diabetes [identified using
International Classification of Diseases version
9 (ICD-9) codes] together with a measurement
of HbA1c C6.5% or BG [6.9 mmol/L. The
diabetes registry also included those
who purchased C2 monthly packs of
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anti-hyperglycemicmedicationduringa6-month
period. The MHS diabetes registry was created for
clinical purposes and its data are routinely
updated by the patient’s physicians, to maintain
a very high level of validity. Patients were
excluded if they were\18 years of age, were
diagnosed with diabetes for \12 months, had
\12 months’ follow-up after their SHE, or if their
type of diabeteswas unknown.Data are presented
for 1 month pre- and 1 month post-SHE. Data
were also collected for 1 week and 12 months pre-
and post-index date to conduct sensitivity
analyses (data not shown).
Patients were included in this analysis if they
had at least one SHE, identified by ICD-9 codes
in the MHS registry between January 1, 2005
and April 30, 2013. Study index date (baseline)
was defined as the earliest date of SHE diagnosis
after a 12-month SHE-free period. This analysis
considers data collected during 1 month before
and after the SHE.
Data retrieved for this study included
sociodemographic details, diabetes duration,
body mass index (BMI), HbA1c, hypertension
and cardiac comorbidities, and healthcare
services utilization. Utilization data included
hospitalizations, emergency department visits,
outpatient visits and laboratory, pathology,
radiology and imaging visits, medication, and
purchases of self-measured blood glucose
(SMBG) strips. The BMI value was the value
taken nearest to the SHE (before or after it).
HbA1c value was the most recent result before
the SHE. Socioeconomic status was based on
residential socioeconomic index, ranging from
1 (lowest) to 20 (highest). In the patient records
where diabetes type was not recorded, a
classification of T1D was made if the patient
was using insulin or had a positive glutamic
acid decarboxylase (GAD) or islet cell antibody,
and was under the age of 40 years. A
classification of T2D was made if the patient
was not using insulin for at least 1.5 years or
had a positive C-peptide test. In other cases, the
diabetes type was classified as unknown and the
patient was excluded from the analysis.
Costs of different healthcare services were
taken from the IsraeliMinistry ofHealth price list
in Israeli new shekels and were converted to $US
dollars. Costs per patient represent mean values
for all patients included in the study. The study
was approved by MHS’ ethics committee and
performed in accordance with the Declaration of
Helsinki [15]. The study was performed
according to the STrengthening the Reporting
of OBservational studies in Epidemiology
(STROBE) Statement for cohort studies [16].
Statistical Analysis
Resource utilization and healthcare costs were
compared in the time period (1 month) before
and after index SHE. Continuous variables
(length of hospital stay and healthcare
expenditure) were compared using a paired
Student’s t test. Chi square (number of
hospitalizations) and McNemar’s tests
(hospital visits comparison) were used to
compare categorical variables. Wilcoxon
signed-rank test was used to compare ordinal
variables (the number of hospitalizations per
patient and expense comparisons).
A Kruskal–Wallis test was used to compare
between-group differences following
stratification by BMI and socioeconomic
status, and a Mann–Whitney test was
used to compare insulin-treated versus
non-insulin-treated groups. Statistical
significance was set at P\0.05. All analyses
were conducted using IBM SPSS software (IBM
SPSS Statistics for Windows, version 21.0,
released 2012, IBM Corporation, Armonk, NY,
USA).
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RESULTS
Study Population
A total of 3975 patients were eligible for
inclusion in the study; their characteristics at
index/time of SHE are summarized in Table 1.
Overall, 7.1% of patients in the study were
categorized as T1D (n = 284), and 92.9% as T2D
(n = 3691). At index, 95.4% of patients with
T1D and 32.8% of patients with T2D were
insulin treated, 3.5% with T1D and 70.4%
with T2D were treated with oral antidiabetic
drugs that could cause hypoglycemia
(sulfonylureas or meglitinides), and 7.7% with
T1D and 76.4% with T2D used oral drugs
known to cause hypoglycemia only rarely
(metformin, gliptins, glitazones, and acarbose).
During 9 years of the study, there were only
slight and insignificant differences in the
number of SHEs reported by patients with
diabetes in the registry each year.
Hospital Visits
In the month following an SHE, 25% (n = 992)
of the study population were hospitalized
and 10% (n = 401) visited the emergency
Table 1 Study population characteristics
Characteristics T1D T2D
n 284 3691
Age, years 29.8 ± 6.7 67.1 ± 11.7
Males, n (%) 149 (52.5) 1756 (47.6)
Duration of diabetes, years, n (%)
\5 97 (34.2) 938 (25.4)
5–9 131 (46.1) 1824 (49.4)
10? 56 (19.7) 929 (25.2)
BMI, kg/m2 25.5 ± 4.6 29.9 ± 5.6
HbA1c, % (most recent prior to SHE) 7.9 ± 1.8 7.3 ± 1.5
Cardiac comorbidity—yes, n (%) 14 (4.9) 1653 (44.8)
Hypertension comorbidity—yes, n (%) 25 (8.8) 2914 (78.9)
Hospitalization a week around index date, n (%) 47 (16.5) 973 (26.4)
Socioeconomic statusa 11.1 ± 4.2 11.3 ± 4.2
Fractures 1 month around SHE, n (%) 3 (1.1) 79 (2.1)
Additional SHE within 12 months of index, n (%)
1 52 (18.3) 661 (17.9)
2 16 (5.6) 173 (4.7)
3 16 (5.7) 159 (4.3)
Data are mean ± standard deviation, unless otherwise speciﬁed
BMI body mass index, SHE severe hypoglycemic event, T1D type 1 diabetes, T2D type 2 diabetes
a On a scale from 1 (lowest) to 20 (highest)
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department. The number of hospital admissions
increased significantly (by 95% for T1D and by
127% for T2D, P\0.001) in the month
following the SHE (Table 2) compared with the
month before the SHE. Additionally, the
proportion of patients with 1, 2, or 3?
hospital admissions also increased significantly
during this period versus the previous month
(Fig. 1). The proportion of patients with T1D
hospitalized on one occasion increased 1 month
post-SHE but there was no increase in the
number of patients requiring two or three
hospitalizations. In patients with T2D, there
was an increase in the proportion of patients
with 1, 2, and 3? hospitalizations 1 month
post- versus 1 month pre-SHE.
Of the patients admitted to hospital pre-
and/or post-SHE (T1D: n = 59, 1.4%; T2D:
n = 1214, 30.5%), the overall mean duration of
stay was significantly longer during the month
post- versus pre-SHE in both patients with T1D
and T2D (T1D: 2.08 vs. 0.88 days, P = 0.036;
T2D: 4.17 vs. 1.45 days, P\0.001; Table 3). The
mean increase in hospital stay post-SHE was
longer in patients with T1D and T2D admitted
for non-surgical procedures and patients with
T2D admitted for surgical procedures, but not
patients with T1D admitted for surgical
procedures (Table 3). Of the 1273 patients who
were hospitalized in the month pre- or
post-SHE, 148 (3.7% of the total study
population; 11.6% of the hospitalized patients)
were hospitalized both in the month pre- and
the month post-SHE. The mean duration of stay
in patients with T2D hospitalized pre- and
post-SHE was significantly longer in the
month post-SHE compared with the month
pre-SHE (9.36 vs. 5.84 days, P = 0.002),
whereas there was no significant difference in
those with T1D (Table 3).
In the month following an SHE, the total
number of outpatient visits increased
significantly from 744 to 1022 (37% increase,
P\0.001) in patients with T1D, and from 10,626
to 15,685 (47% increase, P\0.001) in patients
with T2D. The greatest increases were in visits to
endocrinologists, nurses, and dieticians
(Table 4). There was a non-significant increase
in outpatient pathology, radiology, and imaging
visits, and a significant increase in the number of







Change (%) P value
T1D
Total 68 23 45 95 \0.001
Non-surgical 65 22 43 95 \0.001
Surgical 3 1 2 100 0.861
T2D
Total 1598 488 1110 127 \0.001
Non-surgical 1460 430 1030 139 \0.001
Surgical 138 58 80 37 0.075
Total number of hospitalizations divided according to type of procedure (non-surgical or surgical) and diabetes type.
Analysis conducted using a Chi-square test
SHE severe hypoglycemic event, T1D type 1 diabetes, T2D type 2 diabetes
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lab tests conducted following an SHE in patients
with T2D (Table 4). There was also a significant
increase in the number of medication purchases
post-SHE, including a 61% increase in SMBG
sticks purchases in patients with T2D (P\0.001)
and a 20% increase in diabetic medication
purchases in patients with T1D (P = 0.014;
Table 4).
Cost of Treatment
The increase in frequency and duration of
hospitalization and the frequency of
outpatient visits resulted in a significant
increase in the total costs, hospital costs, and
outpatient costs in the month following an SHE
compared with the month before (Fig. 2). The
total expense per patient per month increased
by 46% (P = 0.001) from $485 to $708 for T1D
and 87% (P\0.001) from $601 pre-SHE to
$1121 post-SHE for T2D. The greatest expense,
and the greatest increase in expense, was
hospitalization, with an increase per patient
per month from $112 to $312 (?179%,
P = 0.003) in T1D, and from $265 to $706
(?166%, P\0.001) in T2D. Additionally, there
was a significant increased expenditure of 37%
in T1D and 46% in T2D for visits to healthcare
specialists, and 34% in T2D for emergency
department visits in the month following an
SHE compared with the month pre-SHE (Fig. 2).
In this analysis, there was no significant change
in the expenses associated with pathology,
radiology, and imaging or lab tests.
As additional sensitivity analyses, healthcare
expenses were also stratified by BMI,
socioeconomic index, whether or not the
patient was insulin treated, Charlson
comorbidity index, and HbA1c (Table 5). There
were no significant differences in expenses
across BMI categories, socioeconomic status,
HbA1c levels, or insulin treatment in both
patients with T1D and T2D. In patients with
T2D, there was a significant increase in expenses
for Charlson index categories, with patients
with Charlson index of ?4 having a 91%
increase in mean expenses per patient in the
month post-SHE versus pre-SHE. No significant
differences for Charlson index categories were
detected for patients with T1D (Table 5).
DISCUSSION
In this real-world, non-interventional analysis
of data from a large-scale diabetes registry,
severe hypoglycemia was associated with
Fig. 1 Proportion of patients with a T1D and b T2D
who had hospital admissions 1 month pre-SHE versus
1 month post-SHE. a P\0.009; b P\0.001 for
comparison of number of hospitalizations pre-SHE versus
post-SHE (Wilcoxon test). SHE severe hypoglycemic
event, T1D type 1 diabetes, T2D type 2 diabetes
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increased use of healthcare services and
resources, resulting in a significant increase in
healthcare expenses in the month following an
SHE compared with the month pre-SHE. These
results indicate that in the month following an
SHE, patients have significantly more frequent
and prolonged hospital admissions and
outpatient visits versus the month pre-SHE.
While it is recognized that factors other than
the SHE could influence the data over the time
period, the non-significant change in
pathology, radiology, and imaging visits would
suggest that there was no change in
concomitant serious illnesses.
The increase in the proportion of patients
with 1, 2, and 3? hospitalizations and the
increase in length of hospital stay 1 month
post- versus 1 month pre-SHE were higher for
patients with T2D compared with T1D, possibly
due to the higher rate of comorbidities and
greater age in these populations. It is possible
that patients with T1D and their carers may also
have more experience at coping with SHEs, and
therefore be less inclined to go to the hospital,
compared with patients with T2D who may not
be insulin treated or have been treated with
insulin for a shorter duration, and therefore
have experienced fewer SHEs. It should also be
noted that the number of patients in the T1D
category was smaller than in the T2D category,
and this may partly explain why the results did
not reach significance. However, other studies
have also shown that hospitalization for severe
hypoglycemia is more frequent in patients with
T2D compared with T1D [10, 17]. These include
a study of the resource use associated with
severe hypoglycemia in insulin-treated patients
with diabetes from a large clinical trial program,
which showed that severe hypoglycemia often
results in the use of emergency services or
Table 3 Mean duration (days) of hospital stay per patient 1 month pre- and 1 month post-SHE
Number of patients 1 month pre-SHE 1 month post-SHE Change (%) P value
All hospitalized patients
T1D
Total 59 0.88 ± 2.32 2.08 ± 3.45 136 0.036
Non-surgical 57a 0.91 ± 2.36 2.21 ± 3.46 142 0.041
Surgical 3a 0.00 0.66 ± 1.15 – 0.423
T2D
Total 1214 1.45 ± 3.28 4.17 ± 8.40 187 \0.001
Non-surgical 1146a 1.29 ± 2.71 3.95 ± 7.68 206 \0.001
Surgical 138a 2.07 ± 5.04 3.85 ± 7.97 85 0.044
Patients hospitalized both pre- and post-SHE
T1D 2 5.50 ± 0.70 7.00 ± 7.07 27 0.830
T2D 146 5.84 ± 5.71 9.36 ± 13.29 60 0.002
Data are mean ± standard deviation for hospitalized patients only. P values are based on a paired t test, which assumes
independence between groups
SHE severe hypoglycemic event, T1D type 1 diabetes, T2D type 2 diabetes
a Some patients had both surgical and non-surgical procedures during the time period assessed
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Table 4 Number of outpatient visits, tests and medication pack purchases 1 month pre- and 1 month post-SHE
1 month pre-SHE 1 month post-SHE Change (%) P value
Outpatient visits
T1D
Endocrinology 78 147 88 \0.001
Nursing care 52 79 51 0.023
Dietician 42 71 69 0.008
Mental care 13 24 84 0.100
General medicine 359 534 48 \0.001
Physiotherapy 17 18 5 1.000
Cardiology 4 1 -75 0.375
Internal medicine 89 95 6 0.712
Ophthalmology 40 23 –42 0.044
Surgery 13 2 –84 0.007
Orthopedics 37 28 –24 0.321
Total 744 1022 37 \0.001
T2D
Endocrinology 346 960 177 \0.001
Nursing care 747 1287 72 \0.001
Dietician 341 556 63 \0.001
Mental care 210 307 46 \0.001
General medicine 6079 9326 53 \0.001
Physiotherapy 595 747 25 \0.001
Cardiology 148 185 25 0.049
Internal medicine 832 962 15 0.002
Ophthalmology 506 556 9 0.133
Surgery 367 376 2 0.769
Orthopedics 455 423 –7 0.295
Total 10,626 15,685 47 \0.001
Outpatient tests
T1D
Pathology, radiology and imaging 9 4 –125 0.166
Lab tests (all) 122 110 –9 0.470
HbA1c tests 83 68 –18 0.225
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ambulance calls and in hospital treatment [17].
Severe hypoglycemia is recognized as a
common cause of hospitalization in elderly
patients with diabetes and those with
comorbidities [18, 19], and in one study
accounted for 94.6% of all endocrine
emergency hospitalizations in older patients
[20].
The results presented here are consistent
with those from several other studies reporting
the extensive resource use and cost
implications of severe hypoglycemia for
healthcare providers/payers. Although the
costs vary depending on the countries
included and their healthcare systems [6,
10–12, 17, 21], together they illustrate that
hypoglycemia is a significant burden and that
efforts to minimize it are likely to reduce the
economic burden of diabetes.
Previous studies into hypoglycemia-related
resource use did not compare the before and
after costs for a specific population of patients.
This study benefits from the pre- and post-event
design, allowing for elucidation of the change
in resource use and expenses to be compared,
while correcting for background resource use. In
support of the robustness of these results,
sensitivity analyses conducted with 1 week and
1 year pre- and post-SHE data showed similar
results (data not shown). The study also benefits
from the level of detail captured and the size of
the population included in the registry.
Following the 1994 Israel National Health Act,
MHS may not deny coverage to applicants on
any grounds, including age or state of health,
and thus these results are a representation of all
sectors of the Israeli population, except for
young adults aged 18–21 years, due to the
Table 4 continued
1 month pre-SHE 1 month post-SHE Change (%) P value
T2D
Pathology, radiology and imaging 203 240 15 0.073
Lab tests (all) 2221 2590 16 \0.001
HbA1c tests 1019 1117 9 0.036
Medication packs
T1D
Total medication 1170 1313 12 0.045
Diabetic medication 493 594 20 0.014
SMBG sticks 492 584 18 0.091
T2D
Total medication 40,711 44,895 10 \0.001
Diabetic medication 8494 8893 4 0.069
SMBG sticks 1774 2864 61 \0.001
Outpatient visits and outpatient tests comparisons were conducted using a McNemar’s test. Medication packs comparisons
were conducted using a Wilcoxon test
SHE severe hypoglycemic event, SMBG self-measured blood glucose, T1D type 1 diabetes, T2D type 2 diabetes
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high percentage of them being enlisted in the
Israeli Defense Forces.
A limitation of this study is that the registry
did not record the cause of SHEs or the reason
why patients were hospitalized, so the primary
reason for hospitalization may not have been
related to diabetes or hypoglycemia in all cases.
Some patients were hospitalized pre-SHE;
however, in the patients who were hospitalized
both pre- and post-SHE, the duration of stay was
significantly increasedpost-SHE, so experiencing
an SHE may have contributed to their longer
hospital stay. The number of patients with T1D
included in the analysis was low, and they may
not be considered a representative sample of
patients with T1D because of their age
([18 years) and late diagnosis age (around the
age of 20 years). It is also not known how many
non-severe hypoglycemia events the study
population experienced during the designated
time period, or whether they contributed to the
increase in resource use observed here;
nonetheless, this should not affect the
conclusion of the study. Furthermore, the
patients’ diabetes-related complications may
also have contributed to resource use.
Fig. 2 Healthcare costs per patient 1 month pre- and
1 month post-SHE total costs for a T1D and b T2D, and
breakdown of outpatient costs for c T1D and d T2D. Cost
comparisons conducted using Wilcoxon test. SHE severe
hypoglycemic event, SMBG self-measured blood glucose,
T1D type 1 diabetes, T2D type 2 diabetes
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Table 5 Total expenses per patient stratiﬁed by BMI, socioeconomic status, and insulin use








P valueb P value
T1D
BMI, kg/m2 (n) \25 (172) 441 740 67 0.004 0.865c
26–30 (80) 571 677 18 0.173
[31 (30) 531 646 21 0.192
Socioeconomic statusa (n) Low (37) 638 708 10 0.839 0.680c
Medium (115) 596 769 29 0.051
High (72) 333 656 96 0.037
Insulin use (n) Yes (271) 494 677 36 0.001 0.883d
No (13) 298 1366 357 0.650
Charlson comorbidity
indexe (n)
Low (166) 448 612 36 0.008 0.385c
Medium (88) 431 730 69 0.212
High (30) 849 1177 38 0.072
HbA1c (n) B7% (99) 538 776 44 0.061 0.984
c
7–9% (122) 420 541 28 0.013
[9% (61) 530 899 69 0.227
T2D
BMI, kg/m2 (n) \25 (908) 652 1271 94 \0.001 0.574c
26–30 (1311) 538 990 83 \0.001
[31 (1358) 564 1007 78 \0.001
Socioeconomic statusa (n) Low (563) 590 955 61 \0.001 0.528c
Medium (1600) 603 1187 96 \0.001
High (1057) 589 1139 93 \0.001
Insulin use (n) Yes (1210) 687 1363 98 \0.001 0.187d
No (2481) 558 1003 79 \0.001
Charlson comorbidity
indexe (n)
Low (776) 315 552 75 \0.001 \0.001c
Medium (1056) 483 865 78 \0.001
High (1859) 787 1504 91 \0.001
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CONCLUSIONS
In conclusion, this real-world analysis of nearly
4000 patients with diabetes who experienced an
SHE documents the healthcare resources used,
and expenses associated with severe
hypoglycemia. The frequency and length of
hospital stay increased, the number of
outpatient visits increased, and the cost of
treatment increased in the month post-SHE
compared with the month pre-SHE.
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